TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial
Brief Summary: Primary objective:

* Comparison of efficacy of the combination therapy (clopidogrel plus aspirin) and the aspirin alone (main comparison) to prevent any recurrent ischemic lesion .

Secondary objectives:

* Comparison of Modified Rankin scale (mRS) scores;
* Comparison of the Incidence of all kinds of stroke and vascular death;
* Comparison of the Incidence of bleeding episodes (major and minor) and symptomatic intracerebral hemorrhages during the follow-up period.


Options:
A: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel, Drug: Aspirin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel placebo, Drug: Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Monotherapy | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Combination therapy, Monotherapy
B: Arm Label: Aspirin + clopidogrel + oral anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Arm Label: Oral anticoagulants + clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Device: PCI (percutaneous coronary intervention) | Intervention Type: DEVICE; Name: PCI (percutaneous coronary intervention); Assigned to Arm(s): Aspirin + clopidogrel + oral anticoagulation, Oral anticoagulants + clopidogrel
C: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
D: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis
Brief Summary: This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.


Options:
A: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
B: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
C: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
D: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis
Brief Summary: This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.


Options:
A: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
B: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
C: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only
D: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study
Brief Summary: The purpose of this research study is to compare the effectiveness of Zolpidem CR to that of placebo in improving sleep efficiency in people with dementia admitted to the hospital because of their symptoms. You can participate in this study if you have dementia of the Alzheimer's type or vascular dementia. This study involves placebo; a placebo is a tablet that looks exactly like Zolpidem CR, the study drug, but contains no active study drug. We will use placebos to see if the study results are due to the study drug or due to other reasons. Zolpidem CR is also called Ambien CR and is widely available by prescription. Zolpidem CR is approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia (trouble falling or staying asleep).


Options:
A: Arm Label: AZD5213 doseA; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseB; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: AZD5213 doseC; Type: EXPERIMENTAL; Interventions: Drug: AZD5213 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseA | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseB | Intervention Type: DRUG; Name: AZD5213; Assigned to Arm(s): AZD5213 doseC | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Mirtazapine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet with increased fruits, vegetables, and calcium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased high impact activity and resistance training; Assigned to Arm(s): N/A
B: Arm Label: Activity prescription; Type: EXPERIMENTAL; Interventions: Other: Activity Knowledge Circuits | Arm Label: Normal Curriculum; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Activity Knowledge Circuits; Assigned to Arm(s): Activity prescription
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy | Arm Label: Screening strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy | Arm Label: Environmental strategy; Type: EXPERIMENTAL; Interventions: Other: Environmental strategy | Arm Label: Educational and Screening strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy | Arm Label: Screening and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy, Other: Environmental strategy | Arm Label: Educational and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Other: Environmental strategy | Arm Label: the three strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy, Other: Environmental strategy | Intervention Type: BEHAVIORAL; Name: Educational strategy; Assigned to Arm(s): Educational and Environmental strategies, Educational and Screening strategies, Educational strategy, the three strategies | Intervention Type: BEHAVIORAL; Name: Screening strategy; Assigned to Arm(s): Educational and Screening strategies, Screening and Environmental strategies, Screening strategy, the three strategies | Intervention Type: OTHER; Name: Environmental strategy; Assigned to Arm(s): Educational and Environmental strategies, Environmental strategy, Screening and Environmental strategies, the three strategies

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Brief Summary: Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total cholesterol levels compared to monotherapy.


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Arm Label: Fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluvastatin | Arm Label: Fluvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin plus ezetimibe | Intervention Type: DRUG; Name: fluvastatin; Assigned to Arm(s): Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin plus ezetimibe; Assigned to Arm(s): Fluvastatin + Ezetimibe
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: a Multicentered Randomised Controlled Trial to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered
Brief Summary: To test the value of preoperatively performed urodynamics with regard to outcome of surgery for stress urinary incontinence (SUI) and to examine whether not performing urodynamics preoperatively is more cost effective than performing urodynamics preoperatively using the non-inferiority assumption.


Options:
A: Arm Label: No UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation | Arm Label: UDS; Type: ACTIVE_COMPARATOR; Interventions: Other: Office evaluation, Other: UDS | Intervention Type: OTHER; Name: Office evaluation; Assigned to Arm(s): No UDS, UDS | Intervention Type: OTHER; Name: UDS; Assigned to Arm(s): UDS
B: Intervention Type: DRUG; Name: SS-RBX; Assigned to Arm(s): N/A
C: Arm Label: surgical therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: midureteral sling | Arm Label: individual management; Type: ACTIVE_COMPARATOR; Interventions: Other: surgical therapy or conservative | Intervention Type: PROCEDURE; Name: midureteral sling; Assigned to Arm(s): surgical therapy | Intervention Type: OTHER; Name: surgical therapy or conservative; Assigned to Arm(s): individual management
D: Intervention Type: PROCEDURE; Name: Urodynamics; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: I-START: Internet-based Strategic Transdisciplinay Approach to Risk Reduction And Treatment
Brief Summary: I-START is a randomized controlled trial that will evaluate the efficacy of an internet-based program of behavioural counseling for adaptive lifestyle change to subjects diagnosed with hypertension. I-START will be evaluated using objective outcome indices: systolic and diastolic blood pressure, pulse pressure, and markers of vagal-heart rate (HR) modulation and baroreflex sensitivity. The Heart and Stroke Foundation of Canada "Blood Pressure Action Plan(TM)" (BPAP) will be adminisered over a 4-month period, and evaluated in a 2 (Intervention vs. Wait list Control) X 2 (Baseline vs. Post-Intervention) factorial design, blocking for 3 recruitment sites (Toronto, London, the Grey Bruce region of Ontario, Canada), and stratified for sex and age group (45-59, 60-74 years).


Options:
A: Arm Label: internet based intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: internet based vascular risk factor intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: internet based vascular risk factor intervention; Assigned to Arm(s): internet based intervention
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic Information | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based lifestyle counseling messages | Intervention Type: BEHAVIORAL; Name: Web-based lifestyle counseling messages; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Generic Information; Assigned to Arm(s): 1
C: Arm Label: Psychodynamic Motivation and Training Program (PMT); Type: EXPERIMENTAL; Interventions: Behavioral: Psychodynamic Motivation and Training Program (PMT) | Arm Label: Advice in Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advice in Exercise Training (+Ex) | Arm Label: Treatment as usual (TAU); Type: OTHER; Interventions: Other: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Psychodynamic Motivation and Training Program (PMT); Assigned to Arm(s): Psychodynamic Motivation and Training Program (PMT) | Intervention Type: BEHAVIORAL; Name: Advice in Exercise Training (+Ex); Assigned to Arm(s): Advice in Exercise Training | Intervention Type: OTHER; Name: Treatment as usual (TAU); Assigned to Arm(s): Treatment as usual (TAU)
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Cardiovascular Outcomes in African Americans With Diabetes
Brief Summary: The goal of this study is to improve cardiovascular disease (CVD) and cholesterol in African Americans adults with diabetes by addressing the modifiable risk factors of systolic blood pressure (SBP), glycosylated hemoglobin (Hb A1c), and low-density lipoprotein cholesterol (LDL-C). We will evaluate the impact of a tailored CVD risk management intervention administered by nurses via the telephone. The intervention incorporates medication management and behavioral modification and will be tailored to the needs of vulnerable high risk subjects (e.g. African Americans, low socioeconomic status, low literate). It will be integrated into community clinics, thereby enhancing the potential for benefit and generalizability to other settings.

The primary hypothesis is that among African American subjects with diabetes, a nurse administered, tailored cardiovascular risk management intervention targeting both medication management and behavioral patient self-management will decrease SBP by 5 mmHg, Hb A1c by 0.5%, and LDL-C by 20 mg/dl over 12 months relative to the cardiovascular education-only control group.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: mobile application for diabetes | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mobile application for diabetes; Assigned to Arm(s): Intervention
C: Arm Label: Care Coordination; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Coordination | Arm Label: Home Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Telemedicine | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Care Coordination | Intervention Type: BEHAVIORAL; Name: Home Telemedicine; Assigned to Arm(s): Home Telemedicine
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored cardiovascular risk management (Nurse-administered ) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored cardiovascular risk management (Nurse-administered ); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant
Brief Summary: Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta (NeoRecormon ®) | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: epoetin beta (NeoRecormon ®); Assigned to Arm(s): A
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
D: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA

Answer: A